secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001193125-22-217351
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Q2 net loss widens to $28.7M; tebipenem HBr NDA receives CRL; Phase 2 SPR720 trial set for Q4 2022
--------------------------------------------------------------------------------

- Net loss $28.7M ($0.87/share) vs $18.6M ($0.63/share) in Q2 2021; revenue $2.0M down from $5.1M.
- FDA issued Complete Response Letter for tebipenem HBr NDA; Type A meeting completed to discuss path forward.
- Phase 2 trial of SPR720 in NTM-PD expected to start Q4 2022; interim data mid-2023.
- SPR206 regulatory milestone achieved under Pfizer license; $5M payment expected in Q3 2022.
- Cash, equivalents and marketable securities $45.4M; believes funding into late 2023 via restructuring.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522217351/0001193125-22-217351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522217351/d297960d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-217351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer